An embolic device by Fluidx Medical has been used successfully in a variety of complex cancer cases, according to a company press release.
As part of an ongoing multicentre study, Fluidx Medical has released additional information on treating tumours, including a highly vascularised metastatic renal cell carcinoma, with the GPX embolic device.
“We were very pleased with the outcome and the resulting occlusion created by GPX,” said Martin Krauss, head of interventional radiology at Christchurch Hospital (Christchurch, New Zealand.) “In one procedure, the renal cell carcinoma had metastasised to the upper femur/pelvic region. We used a combination of GPX and coils during the case. We treated five different tumour vessel segments with GPX.”
“GPX successfully occluded a variety of vessel presentations from smaller low-flow vessels to larger higher-flowing feeding vessels,” said Christopher Phillips, director of clinical affairs at Fluidx. “GPX was delivered using a range of microcatheters and showed versatility in treating small and large metastatic tumour vessel beds. GPX was delivered through standard microcatheters that were appropriate for each targeted vessel’s size and blood flow.”
The GPX embolic device is designed for simple preparation and controlled delivery. The company advises that the device is packaged ready to use in a syringe, can be prepped tableside by the clinician in about 30 seconds, and may be delivered through standard microcatheters.
Fluidx Medical describes its GPX technology as a low-viscosity, aqueous-based solution in a syringe that solidifies into a durable embolus upon delivery, without polymerisation or dimethyl-sulfoxide (DMSO) precipitation. GPX is designed to occlude blood vessels independent of a patient’s coagulation situation.